I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: M1774|DRUG: Fulvestrant injection
Sponsor: Institut Paoli-Calmettes
Collaborators: Merck Sharp & Dohme LLC|National Cancer Institute, France